Vor Biopharma (VOR) Capital Expenditures (2020 - 2026)

Vor Biopharma (VOR) has reported Capital Expenditures for 7 consecutive years, with $48000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Capital Expenditures changed N/A year-over-year to $48000.0; the TTM figure through Mar 2026 stood at $989000.0 (up 760.0% YoY), while the FY2025 annual figure was $941000.0, up 310.92% from the prior year.
• Capital Expenditures slipped to $48000.0 in Q1 2026 per VOR's latest filing, from $314000.0 in the prior quarter.
• Across five years, Capital Expenditures topped out at $5.8 million in Q2 2022 and bottomed at -$7.8 million in Q3 2022.
• Historically, Capital Expenditures has averaged $82875.0 across 5 years, with a median of $93000.0 in 2024.
• Annual changes were most pronounced in 2023 — Capital Expenditures tumbled 4833.33% — and 2025, when it surged 4155.56%.
• Vor Biopharma's Capital Expenditures stood at -$18000.0 in 2022, then sank by 4833.33% to -$888000.0 in 2023, then soared by 108.11% to $72000.0 in 2024, then surged by 336.11% to $314000.0 in 2025, then sank by 84.71% to $48000.0 in 2026.
• Business Quant data shows VOR's Capital Expenditures at $48000.0 in Q1 2026, $314000.0 in Q4 2025, and $244000.0 in Q3 2025.